CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Mar. 28, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 3,254	$ 9,852
Short-term investments	2	253
Accounts receivable, less allowances of $149 and $147	9,204	8,900
Inventories	5,496	5,425
Contract assets, net	1,684	1,666
Other current assets	2,677	2,612
Total current assets	22,316	28,707
Property, plant and equipment, net	10,658	10,565
Acquisition-related intangible assets, net	19,146	15,838
Other assets	5,973	5,871
Goodwill	55,187	49,362
Total assets	113,281	110,343
Current liabilities:
Short-term obligations and current maturities of long-term obligations	3,090	3,533
Accounts payable	3,344	3,622
Accrued payroll and employee benefits	1,565	1,995
Contract liabilities	2,928	2,710
Other accrued expenses	3,694	3,329
Total current liabilities	14,621	15,189
Deferred income taxes	2,107	1,493
Other long-term liabilities	4,421	4,273
Long-term obligations	40,071	35,852
Redeemable noncontrolling interest	121	122
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	0	0
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,473,074 and 445,160,301 shares issued	445	445
Capital in excess of par value	18,713	18,563
Retained earnings	60,632	59,156
Treasury stock at cost, 73,851,609 and 68,938,831 shares	(25,360)	(22,309)
Accumulated other comprehensive income/(loss)	(2,497)	(2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity	51,934	53,407
Noncontrolling interests	7	7
Total equity	51,940	53,415
Total liabilities, redeemable noncontrolling interest and equity	$ 113,281	$ 110,343